All the latest worldwide HIV and AIDS news, including treatment, prevention, and hepatitis and TB co-infections. News from our own team of writers plus articles we have selected from other sources.

aidsmap hiv & aids news

RSS

hiv & aids news selected from other sources

  • The search for an HIV prevention vaccine
    HVTN's large-scale HIV vaccine efficacy trials fully enrolled
    HIV Vaccine Trials Network | 24 June 2019

    The HIV Vaccine Trials Network (HVTN), headquartered at the Fred Hutchinson Cancer Research Center, has fully enrolled its four ongoing large-scale HIV vaccine efficacy trials. The clinical trials, underway on four continents in 12 countries, are made possible by 12,669 study participants and the collaborative efforts of HVTN study teams, all on a journey to find a safe and effective HIV vaccine. Complete enrollment facilitates the collection and analysis of trial-specific data, enabling researchers to answer research questions.

  • Access to medicines and treatment
    Kenya: 69,000 newborns at risk due to ARVs shortage
    The Nation | 24 June 2019

    Medical personnel at several public hospitals who spoke to the Nation on the condition of anonymity said the shortage began about four months ago. They said the situation is dire, and that if no intervention is made urgently, things could turn disastrous. The administration of ARVs to newborns without HIV is meant to reduce the risk of mother-to-child transmission (perinatal acquisition).

  • Global health initiatives
    Exclusive: UNAIDS executive shortlist
    Devex | 24 June 2019

    Five candidates are competing for the top job at the Joint United Nations Programme on HIV/AIDS to replace Michel Sidibé, who led the organization since 2009 and left in May this year amid controversy. The shortlist includes only one woman and four men.

  • HIV prevention policy
    Vaginal ring can substantially impact HIV prevention, reveals mathematical model
    Avert | 24 June 2019

    New mathematical modelling study suggests that the dapivirine vaginal ring could substantially reduce HIV infections among South African women and be an affordable intervention depending on roll-out strategy.

  • Human rights
    The Slow Rollout Of PrEP Is Denying Gay Men Their Right To Human Dignity
    Huffington Post | 24 June 2019

    Gay men are already a socially marginalised and stigmatised group – their health can no longer continue to be sacrificed, National AIDS Trust's Yused Azad writes

  • HIV treatment for children and young people
    Biktarvy Approved to Treat Pediatric Patients With HIV-1
    Monthly Prescribing Reference | 20 June 2019

    he Food and Drug Administration (FDA) has approved updated labeling for Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide; Gilead) to include treatment of both adult and pediatric patients weighing at least 25kg with HIV-1 who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy. Previously, the combination therapy had only been approved for adults.

  • PrEP science
    CytoDyn Signs Groundbreaking Memorandum of Understanding with Thai Red Cross AIDS Research Centre to Study Pre-Exposure Prophylaxis Use of Leronlimab (PRO 140) in People at High Risk of Acquiring HIV
    CytoDyn press release | 20 June 2019

    “The rationale for the use of leronlimab as PrEP is grounded in the long-standing observation that individuals deficient for the CCR5 co-receptor are nearly completely resistant to sexual transmission of HIV,” said Dr. Jonah Sacha, Associate Professor of the Oregon Health & Science University. Dr. Sacha continued, “Given the difficulties many patients face with adherence to daily oral antiretroviral therapy drugs as PrEP, once-weekly leronlimab as PrEP could be transformative in slowing the epidemic.”

  • New and experimental HIV treatments
    CytoDyn Announces Major Discovery for its Monotherapy Indication
    CytoDyn press release | 20 June 2019

    CytoDyn, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today significant progress in securing the therapeutic effect and safety of leronlimab (PRO 140) with the development of an assay that can reliably determine a patient’s CCR5 status.

  • Delivery of care
    1 in 10 People With Diagnosed HIV Must Drive Over 1 Hour for Care
    Poz | 20 June 2019

    Such lengthy commutes for HIV care among those with diagnosed with the virus may impede efforts to control the epidemic.

  • People who inject drugs
    India’s injecting epidemic – a problem for young people
    Avert | 20 June 2019

    People between the ages of 18-30 who inject drugs in India, are a critical sub-population driving the HIV epidemic in the country.

Conference news

News from the 25th Annual Conference of the British HIV Association (BHIVA).

EUROBulletin

Sign up for our Sexual Health & HIV Policy EUROBulletin.

HIV update

Sign up for HIV update, our fortnightly news bulletin for people living with HIV in the UK.

aidsmapLIVE

Watch our AIDS 2018 aidsmapLIVE panel discussion on YouTube.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.